CART Grants

Research Center and Lead Scientists

• 1999 Emory University: Allan I. Levey, M.D. Ph.D. and Jim Lau
• 2001 Case Western Reserve University: Karl Herrup, Ph.D. and Gary Landreth
• 2002 Johns Hopkins University: Philip C. Wong, Ph.D. and Donald Price
• 2003 University of Pennsylvania: John Q. Trojanowski, M.D. Ph.D.
• 2004 University of Connecticut Health Science Center: Robert Reenan, Ph.D.
• 2005 University of California, Los Angeles: Gary Small, M.D.
• 2006 University of Texas Medical Branch: Claudio Soto, Ph.D.
• 2007 Mayo Clinic Jacksonville: Todd E. Golde, M.D., Ph.D.
• 2008 The Cleveland Clinic: Sanjay W. Pimplikar, Ph.D.
• 2008: The University of Alabama-Birmingham Medical Center: J. David Sweatt, Ph.D.
• 2009: University of Kentucky: Harry LeVine.III, Ph.D.
• 2009: Mayo Clinic, Jacksonville, Fl: Malcom LeissringS, Ph.D.

• 2010 Two Major Grants:
  
  * Paul Murphy, University of Kentucky ($250,000 2yr. Grant)>

  Paul Murphy, University of Kentucky ($250,000 2yr. Grant)

  Alzheimer's disease is sometimes called "the diabetes" of the brain, because, like diabetes, it is common and shares some common features including accumulation of proteinaceous deposits called amyloid. Moreover, until recently, it wasn't apparent that diabetes itself is a risk factor for AD, and insulin, a key hormone regulating the body's ability to respond to glucose ("sugar") levels in the blood and centrally involved in the pathogenesis of diabetes, also has important effects on brain cells and the cellular and molecular processes involved in AD. Dr. Murphy's exciting research proposal will study the shared mechanisms involved in AD and diabetes, and another new link between them - obesity.

  Close Paul Murphy's Info ^

  * Luigi Puglielli, University of Wisconsin ($150,000 2 yr Grant)>

  Luigi Puglielli, University of Wisconsin ($150,000 2 yr Grant)

  Accumulation of a toxic protein fragment known as the amyloid beta peptide (Aß) in the brain is belieed to play an important role in Alzheimer's disease., and as such, there is worldwide interest in developing new ways to reduce the build up Aß in the brain as a therapeutic strategy for prevention and treatment of AD. Dr. Puglieili's CART research grant takes an entirely novel and promising approach to reducing amyloid production in the brain. His research will capitalize on promising preliminary finding s and discovery of new drug-like compounds that appear to change the activity of another key protein, called BACE1 (the Beta Amyloid Converting Enzyme). Further development of these and other related compounds in this research could lead to new drugs that reduce Aß production in a more safe way than other strategies under development.

  Close Luigi Puglielli's Info ^

  * Kurt Burnden, Pennsylvania State University ($50,000 year Grant) >

  Kurt Burnden, Pennsylvania State University ($50,000 year Grant)

  Dr. Burnden's proposal is close behind Puglieli's in terms of proximity to animal model testing, after Brunden does some toxicology. Brudens proposal focuses on a family of aminothienopyridizine (ATPZs) compounds that emerged from 290,000 compound screens for drugs to block tangle formation in AD. He has identified several ATPZs that are worthy of bringing forward in animal studies.

  Close Kurt Burnden's Info ^

Research centers from all over the USA submit 40 to 50 applications for CART grants annually. Grants are based on the income received each year. CART policy is to confine grants to researchers working in the United States. Read more about the grants CART Fund has given.